NASDAQ:GTBP GT Biopharma Q3 2026 Earnings Date & Estimates $3.90 -0.42 (-9.72%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. GT Biopharma is estimated to report Q3 2026 earnings on Friday, November 13, 2026. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 13, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from GT Biopharma in Q3 2026GT Biopharma is expected to post earnings of -$2.50 per share. In the same quarter a year earlier GT Biopharma reported -$20.75 per share. GT Biopharma last reported on August 14, 2026, posting -$0.12 per share and missing the -$0.08 consensus estimate. GT Biopharma has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$2.50Prior-Year EPS-$20.75Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.12 (Missed by -$0.04)EPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report GT Biopharma Q3 2026 Earnings FAQ When does GT Biopharma report Q3 2026 earnings? GT Biopharma (NASDAQ:GTBP) is estimated to report Q3 2026 earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is GT Biopharma's Q3 2026 earnings call? GT Biopharma's Q3 2026 earnings conference call is scheduled for Friday, November 20, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for GT Biopharma? Analysts expect GT Biopharma to post earnings of -$2.50 per share for Q3 2026. GT Biopharma Earnings HeadlinesGT Biopharma Explores A New Combination Approach For Pancreatic Cancer4 hours ago | finance.yahoo.comGT Biopharma Oral Presentation at the SITC 2026 Annual MeetingNovember 9 at 1:06 PM | finance.yahoo.comMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a household name. Now he says a similar shift is unfolding in AI infrastructure. Hundreds of billions are pouring into AI data centers, but he warns the builders could get crushed by their own costs while one overlooked sector absorbs the spending.November 10 at 1:00 AM | Porter & Company (Ad)GT Biopharma (GTBP) Projected to Announce Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comGT Biopharma Selected for Oral Presentation at the SITC 2026 Annual MeetingOctober 26, 2026 | markets.businessinsider.comGT Biopharma Regains Nasdaq Minimum Bid ComplianceSeptember 27, 2026 | theglobeandmail.comSee More GT Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GT Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GT Biopharma and other key companies, straight to your email. Email Address About GT BiopharmaGT Biopharma (NASDAQ:GTBP) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research centers on natural killer (NK) cells, a component of the immune system that can recognize and destroy abnormal cells. GT Biopharma’s principal technology is its TriKE (trispecific killer engager) platform. These engineered molecules are designed to bind a cancer-associated target, activate NK cells through the CD16 receptor, and enhance NK-cell activity through an interleukin-15 component. The company has applied this approach to blood cancers, including acute myeloid leukemia and other hematologic malignancies. The company has advanced investigational programs such as GTB-3550, an NK-cell engager designed to target CD33-expressing cancer cells, along with additional programs directed at targets including CD33 and CD19. GT Biopharma’s development activities have primarily focused on clinical and preclinical oncology research in the United States. Its therapies remain investigational and require further clinical evaluation to establish their safety and effectiveness.View GT Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
